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Summary 
The risk factors for contracting symptomatic COVID-19 are not yet fully understood, age and certain 
underlying health conditions are considered to be detrimental in this respect. Case studies revealed 
an astonishingly low number of current smokers among patients suffering from symptomatic 
COVID-19 compared to the general population, leading to the conclusion that smoking/nicotine 
uptake might have a preventive effect. This is difficult to understand seeing that studies found an 
increased expression of the angiotensin-converting enzyme (ACE-2) in smokers, the entrance gate 
of the coronavirus into human cells. Consequently, the use of the proportion of smokers in the 
general population as a reference for deriving prevalence ratios to study the association of smoking 
with COVID-19 disease outcomes may be inappropriate. Prevalence data for smoking and 
comorbidities (hypertension, diabetes mellitus, and chronic obstructive pulmonary disease) reported 
in 25 studies, which partially identified a potentially beneficial effect of smoking/nicotine intake, 
were re-analysed to investigate the relationship between COVID-19 mortality and national smoking 
prevalence taking account of known risk factors associated with mortality. The limited agreement of 
the prevalence of those risk factors in the general population with the cohort data demonstrates 
indirectly that these patients most likely do not reflect the health status of the general population. 
In the absence of specifically designed studies, any hypothesis on the effect of nicotine on 
symptomatic COVID-19 remains speculative. The number of potentially confounding variables 
would require a multivariate statistical approach and large cohort sizes for providing clarity on the 
significance of potential effects. However, the structure of the published aggregated data permits 
only univariate approaches. As such, the hypothesis of a potentially protective effect of nicotine on 
symptomatic COVID-19 cannot be verified.  
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Introduction 
The conclusions from a cross sectional study conducted by French scientist that smoking might 
protect against symptomatic infections with the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) has caused both a lot of attention in public media and shockwaves among tobacco 
control organisations (1). The response of the public, exposed to uncertainty and fear about SARS-
CoV-2 infections, was so massive, that the French Ministry of Health imposed on 23 April 2020 
temporary restrictions on the sale of nicotine supplying therapeutics, which are usually used in 
smoking cessation therapy (2, 3). The respective ministerial decree reasoned the measure with 
prevention of self-medication and overdosing of nicotine, and ascertaining an uninterrupted supply 
of the products for therapeutic purposes. There is also anecdotal information about an increase in 
cigarette prices in Iran, due to an increased demand of tobacco products after the publication of 
the French study. France, however, declared at the virtual meeting of the G7 health ministers to 
further study the potentially positive effect of nicotine in fighting the coronavirus disease 2019 
(COVID-19).  
It is without surprise that the tobacco control community issued warnings and advised strongly 
against (commencing) smoking for preventing COVID-19.  
Questions, which have to be addressed in this context, are whether smoking, respectively nicotine 
uptake, have any effect on COVID-19, and if so, what is the magnitude of the effect. Press reports 
relating the low number of smokers with symptomatic COVID-19 to beneficial effects of smoking 
do not properly reflect the current scientific debate, which centres on physiological effects of 
nicotine uptake and not on smoking.  
It has to be noted that most publications on the possible link between smoking (nicotine 
consumption) and COVID-19 outcomes provide plausible hypotheses, but lack experimental 
evidence. Much of the relevant information is still under peer review and published on pre-print 
portals only.  
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Nicotine, the Renin-Angiotensin System and COVID-19 
There is large agreement in the scientific community that SARS-CoV-2 enters host cells via the 
angiotensin-converting enzyme 2 (ACE2), a transmembrane protein with both extracellular and 
intracellular components (4-7). ACE2 is part of the renin-angiotensin system (RAS), which exerts 
different functions in the human body, among them it is involved in the regulation of blood 
pressure (8). Downregulation of ACE2 in virus-infected cells triggers a response of the immune 
system, including the production of pro-inflammatory cytokines, which can lead to a so-called 
‘cytokine storm’ resulting in multi-organ failure and, ultimately, leading to death (6).  
Any intervention in the homeostasis of the RAS system may have consequences regarding the 
susceptibility to SARS-CoV-2 infections and outcomes of COVID-19. Pharmaceutical interventions 
and environmental as well as individual behavioural factors, such as nicotine consumption via 
smoking, could intervene in RAS homeostasis (9, 10). 
Nicotine binds in the human body to the nicotinic acetylcholine receptor, which is expressed in many 
body tissues. Several biochemical mechanisms are used to explain a hypothetical effect of nicotine 
on COVID-19 outcomes and the low prevalence of smokers among hospitalised COVID-19 patients: 
• A nicotine dependent downregulation of the expression of the ACE2 receptor in several 
body tissues could limit the number of entry gates for SARS-CoV-2. 
• The inhibitory effect of nicotine on the production of pro-inflammatory cytokines, which led 
to adverse outcomes in COVID-19 patients if released in overwhelming amounts (“cytokine 
storm”). 
• The immune system of current smokers might be more tolerant and less prone to the over-
production of immune cells and cytokines compared to immunocompetent non-smokers, 
reducing thereby the likelihood of the development of acute respiratory distress syndrome 
(ARDS). 
Contrary to the described effects, several authors found higher ACE2 gene expression levels in 
small airway epithelial cells of smokers and COPD patients compared to former smokers and never 
smokers (11, 12).  
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Smoking and COVID-19 
The basis for triggering a debate regarding a possible beneficial effect of smoking is formed by 
several retrospective studies on clinical characteristics and comorbidities of hospitalized COVID-19 
patients (1, 13-37).  
Earlier meta-analyses aimed to elucidate the effect of smoking on the prevalence and severity of 
COVID-19 (35, 38-43). They analysed studies with large differences in cohort sizes and inconsistent 
endpoints (Table 1). Only Vardavas and Nikitara (Relative Risk1 (RR)=2.4; 95% CI 1.43-4.04) and 
Farsalinos et al. (Odds Ratio2=1.53; 95% CI 1.06-2.20) demonstrated that the severity of the illness 
and the fatality rate of active smoker hospitalised for COVID-19 is worse compared to non-
smokers (38, 43). The majority of meta-analyses did not identify statistically significant effects, or 
only a questionable effect of smoking on the severity of COVID-19 (39-41). The latter was 
observed in a meta-analysis of case studies by Zhao et al., who reported for active smokers a 
doubling of the risk to develop sever COVID-19 compared to non-smokers (weighted odd ratio of 
about two), which vanished after breaking down and compiling studies according to differences in 
endpoints (40).  
Contrary to meta-analyses that resulted in either no observable effects of smoking or a negative 
influence on the progression of COVID-19, several meta-analyses pointed out that the number of 
smokers among hospitalised COVID-19 patients was low in comparison to the smoking habits of 
the underlying general population. The very same was reported by Simons et al. (44) in their most 
recent version of the living rapid evidence review on the association of smoking status with SARS-
CoV-2 infection, hospitalisation and mortality from COVID-19. The sixth version of this living rapid 
evidence review compiles information from 174 observational studies stratified by smoking status.  
 
                                           
1 RR compares the risk of a health event (disease or death) among one group with the risk among another 
group. A risk ratio of 1.0 indicates identical risk among the two groups. 
2 OR represents the odds that an outcome will occur given a particular exposure, compared to the odds of the 
outcome occurring in the absence of that exposure. 
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Table 1: Overview on meta-analyses 
 Studies Subjects Former Smoker Endpoint Indicator Pooled Effect* 
       
Lippi et al. (39) 5 1399 No information Severe/non-severe COVID-
19 
OR OR=1.69 (0.41-
6.92) 
Vardavas & Nikitara (38) 5 1549  1) Severe/non-severe 
COVID-19, 
 
2) ICU admission, 
mechanical 
ventilation, death 
1) RR 
 
 
2) RR 
1) RR=1.4 (0.98-
2.00) 
 
2) RR=2.4 (1.43-
4.04) 
Farsalinos Barbouni 
Niaura (42) 
13 5960 1) Left out 
 
2) Pooled with smoker 
Smoking prevalence P 1) P=6.5% 
(4.9%-8.2%) 
2) P=7.3% 
(5.7%-8.9%) 
Farsalinos et al. (43) 18 6515 Included in non-current 
smoking 
1) Current smoking 
 
2) Adverse outcome 
1) POR 
 
2) OR 
1) POR=0.20 
(0.16-0.25) 
2) OR=1.53 
(1.06-2.20) 
Zhao et al. (40) 7 
 
 
1) 4 
 
 
2) 3 
1726 
 
 
1) 1216 
 
 
2) 329 
Included in non-
smoker 
Severity of COVID-19 
 
 
1)Subgroup ISU, 
Ventilation or death 
 
2)Severe COVID-19 or 
disease progression 
OR 
 
 
1) OR 
 
 
2) OR 
OR=1.97 (0.95-
0.27) 
 
1) OR=1.43 
(0.49-4.22) 
 
2) OR=2.86 
(0.73-11.24) 
Gonzales Rubio et al. (41) 18 7671 Included in non-
smoker 
Smoking prevalence OR OR=0.18 (0.14-
0.22) 
OR: Odds ratio, POR: Prevalence odds ratio, P: Prevalence, RR: Relative risk  
* 95% confidence intervals given within brackets 
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The outcomes of the published meta-analyses have to be interpreted with caution, as different 
assumptions were made about the prevalence of non-smokers in the different cohorts, which was 
caused by the lack of explicit data on former smokers and non-smokers. Consequently, subjects not 
identified as smoker were considered as non-smoker. If data on former smokers were available, 
they were grouped partially with current smokers (42) and partially with non-smokers (40, 43). The 
meta-analyses used also different indicators for the evaluation and interpretation of the studies. A 
common limitation to all presented meta-analyses is the fact that most of the data stem from 
retrospective case studies, which did not consider confounding variables. Simons et al. identified a 
number of issues, which could introduce bias respectively complicate at least the interpretation of 
the observational studies (44). The selection of the subjects included in the published studies 
occurred according to criteria such as hospitalisation, development of severe pneumonia, or other 
endpoints. Additionally, the double accounting of patient data in different studies cannot be 
excluded, e.g. the two publications of Guan et al. comprise likely overlapping study cohorts (13, 14). 
The same is expected for data published by the CDC, and by Goyal et al., which concern 
geographically overlapping areas (30, 37).  
The characteristics of the analysed cohorts as well as the reported smoking status is summarized 
in Table 2. All cohorts had lower numbers of smokers in comparison to the number of smokers in 
the related population. The calculated prevalence ratios (PR) were with two exceptions significantly 
below unity. This data is irritating, as it is reasonable to expect that outcomes from COVID-19 
infection are worse for smokers, as is the case in other acute respiratory infections.   
Patients in most of the studied cohorts were of high average age, triggering the question whether 
smoking prevalence data of the general population forms a valid basis for making comparisons. 
Although none of the studies explicitly claimed that the investigated cohorts are representative for 
the general population. Providing further evidence that the studied cohorts reflect health related 
conditions of the general population could be useful for substantiating the potential effect of 
nicotine uptake on the progression of COVID-19 in hospitalised patients.  
This question was approached by investigating whether data on comorbidities reported in the 
cohort studies correlate with the related data of the underlying populations. Data on the non-
communicable diseases hypertension, diabetes mellitus, and chronic obstructive pulmonary disease 
(COPD) were extracted from the cohort studies and combined with published prevalence data for 
these illnesses. This allowed estimating the theoretical number of comorbidity cases in the studied 
cohorts if prevalence rates of the general population were assumed. The investigation was centred 
on 25 studies forming the basis for early meta-analyses, which partially identified a potentially 
beneficial effect of smoking/nicotine intake. 
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Table 2: Observed and expected smoker, prevalence ratio (PR), and probability that observed population is representative for general population  
Author Country Obs. Male Female Smoker 
obs. 
Smoker 
ratio  
obs. 
95% CI, 
LL 
95% CI, 
UL 
Smoker 
exp. 
Smoker 
ratio  
exp. 
PR P-Value 
 
  #   #    #    
Zhang et al. (16) CN 133 0.507 0.493 2 0.015 0.002 0.053 37 0.278 0.05 0.000 
Huang et al. (18) CN 41 0.732 0.268 3 0.073 0.015 0.199 16 0.390 0.19 0.000 
Guan, Ni et al. (14) CN 1099 0.582 0.418 137 0.125 0.106 0.146 346 0.315 0.40 0.000 
Yang et al. (15) CN 52 0.673 0.327 2 0.038 0.005 0.131 19 0.365 0.11 0.000 
Guan, Liang et al (13) CN 1590 0.569 0.424 111 0.070 0.058 0.084 489 0.308 0.23 0.000 
Chen et al. (19) CN 274 0.624 0.376 7 0.026 0.011 0.053 92 0.336 0.08 0.000 
Liu et al. (17) CN 78 0.500 0.500 5 0.064 0.021 0.143 21 0.269 0.24 0.000 
Zhou et al. (20) CN 191 0.623 0.377 11 0.058 0.029 0.101 64 0.335 0.17 0.000 
Zhang, Cai et al. (23) CN 645 0.509 0.491 41 0.064 0.046 0.086 179 0.278 0.23 0.000 
Wang et al. (27) CN 125 0.568 0.432 16 0.128 0.075 0.200 38 0.304 0.42 0.000 
Wan et al. (22) CN 135 0.533 0.467 9 0.067 0.031 0.123 39 0.289 0.23 0.000 
Shi et al. (24) CN 474 0.532 0.468 40 0.084 0.061 0.113 141 0.297 0.28 0.000 
Feng et al. (28) CN 454 0.569 0.431 44 0.097 0.071 0.128 147 0.324 0.30 0.000 
Ji et al. (29) CN 208 0.563 0.438 19 0.091 0.056 0.139 63 0.303 0.30 0.000 
Li et al. (26) CN 544 0.509 0.491 41 0.075 0.054 0.100 153 0.281 0.27 0.000 
Mo et al. (21) CN 155 0.555 0.445 6 0.039 0.015 0.083 47 0.303 0.13 0.000 
Kim et al. (25) KR 28 0.536 0.464 5 0.179 0.061 0.369 6 0.214 0.83 0.855 
Goyal et al. (30) US 393 0.606 0.394 20 0.051 0.031 0.078 83 0.211 0.24 0.000 
CDC (37) US 7162 - - 96 0.013 0.011 0.016 1411 0.197 0.07 0.000 
Gold et al. (36) US 305 0.495 0.505 16 0.052 0.030 0.083 61 0.200 0.26 0.000 
Miyara et al. (1)* FR 341 0.601 0.399 21 0.062 0.039 0.093 89 0.259 0.24 0.000 
Miyara et al. (1)** FR 132 0.460 0.547 13 0.098 0.054 0.160 35 0.252 0.39 0.000 
Miyara et al. (1)*** FR 473 0.560 0.442 34 0.072 0.050 0.099 125 0.259 0.28 0.000 
Han et al. (31) CN 17 0.353 0.647 3 0.176 0.038 0.434 3 0.176 1.00 1.000 
Jin et al. (32) CN 651 0.492 0.508 41 0.063 0.046 0.084 176 0.270 0.23 0.000 
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Lian et al. (33). CN 788 0.516 0.484 54 0.069 0.052 0.089 222 0.282 0.24 0.000 
Yao et al. (34) CN 108 0.398 0.602 4 0.037 0.010 0.092 24 0.222 0.17 0.000 
Zhang, Ouyang et al. 
(35) 
CN 120 0.358 0.642 6 0.050 0.019 0.106 24 0.200 0.25 0.000 
1 hospitalized patients; 2 non-hospitalized patients; 3 all patients;  
PR: prevalence ratio; obs.: observed; exp.: expected; 95% CI: 95 % confidence interval; LL: lower limit; UL: upper limit 
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Exploratory data analysis 
Information on the smoking status and comorbidities of the investigated cohorts were compiled 
from the respective publications. Prevalence ratios for smoking were calculated for the studied 
cohorts taking into account the actual number of subjects for which information on smoking status 
was specified. The expected prevalence ratios for active smokers were determined for the given 
cohort sizes respecting gender and country dependent differences. Actual data on the smoking 
status and prevalence of hypertension, diabetes mellitus and COPD in the respective countries was 
retrieved from public sources (Table 3). Hypertension rates for Chinese cohorts were adjusted for 
gender and geographical region applying rates specified in the electronic supplement of Wang et al. 
(45). The expected hypertension prevalence of subjects from 30 respectively 31 provinces were 
estimated with hypertension rates for the general Chinese population, whereas averages of 
province dependent rates were used in case data comprised subjects from more than one province 
(45). Country-specific diabetes prevalence data were retrieved for China, France and Korea from 
the International Diabetes Federation (IDF), which however did not allow discriminating according to 
gender, and from Virani et al. for the USA (46, 47). Chronic obstructive pulmonary disease (COPD) 
occurs mainly at elderly people. For this reason prevalence data are often provided only for certain 
age groups, such as Chinese and Korean adults above 40 years of age (48, 49). Applying them to 
the general population will likely overestimate the prevalence of COPD in that country. Additionally, 
available prevalence data are associated with significant uncertainties and might be subject to 
geographical variations (50). It should also be noted that some COPD prevalence data is already 
more than a decade old and might not anymore reflect the current situation (51). Acknowledging 
these limitations, they might nonetheless be applicable to the studied cohorts as the average age 
of the cohorts was mostly high as well. Most recent US countrywide prevalence data was preferred 
to older federal state specific prevalence data (50, 52).  
Table 3: Smoking prevalence and prevalence of comorbidities in the countries of the studied 
cohorts 
  Smoking Hypertension Diabetes 
mellitus 
COPD 
 
Data sources  (53-56) (45, 47, 57, 58) (46, 47) (48-51) 
Gender  M F M F M F M F 
Country/Region  % % % % % % % % 
FR  28.2 22.9 36.5 25.2 7.6 7.5 
KR  35.8 6.5 35.0 22.9 9.2 21.6 5.8 
US  25.8 14.1 49.0 42.8 10.9 8.9 6.4 
CN  52.1 2.7   10.9 19 8.1 
CN- Hubei    19.7 16.5     
CN- Chongqing    20.4 20.7     
CN- Zhejiang    25.4 21.0     
CN- Anhui, Hubei, 
Shanghai 
   23.8 21.3     
CN- 30/31 provinces    24.5 21.9     
M: male; F: female 
FR: France; KR: South Korea; US: United States of America; CN: People’s Republic of China 
Expected occurrence figures and occurrence rates were calculated for the studied cohorts taking 
into account the respective cohort size and prevalence data given in Table 3. Occurrence figures 
were rounded to the next integer. Occurrence rates calculated for the studied cohorts were 
complemented by their 95% confidence intervals. Statgraphics Centurion 18 (Statgraphics 
Technologies Inc) was applied for that purpose, as well as for deriving respective probability values.  
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Findings 
Exploratory data analysis confirmed the mismatch of the observed number of smokers with the 
number of smokers expected for the cohort size in the general population. Prevalence ratios for 
smoking were with the exception of two studies significantly below one and p-values usually close 
to zero. These observations formed the basis for the hypothesis that nicotine uptake might have a 
protective effect against symptomatic COVID-19. However, the figures demonstrate only a 
difference between the number of observed smokers and the number of smokers expected for the 
particular cohort. Nonetheless, the plausibility of the hypothesis of a protective effect of nicotine 
against symptomatic COVID-19 would be supported if it could be demonstrated that prevalence in 
the general population of other medical conditions is reflected in the published cohort data.  
The investigation of hypertension, diabetes, and COPD revealed for many cohorts a statistically 
significant discrepancy between the observed prevalence and the prevalence in the general 
population. As for smoking, the observed prevalence was frequently lower than the one expected in 
the general population. A compilation of prevalence ratios is provided in Table 4. Figures in red 
indicate at the 95 % confidence level a significantly lower prevalence observed in the studied 
cohorts compared to the prevalence expected in the general population of the respective country, 
figures in green indicate the opposite, and figures in black were not statistically significant (95% 
confidence level) different from the general population.  
The power of the applied binomial test is strongly influenced by the size of the cohort. The smaller 
it is the lower is the power of the test, which explains the lack of statistical significance of some 
prevalence ratios largely different from one in either direction (Table 4). The situation changes with 
large cohort sizes, for which reason it is even more astonishing that the patients in the largest 
cohorts did not match the prevalence for any of the four features in the general population. This, 
however, must be interpreted with caution, as some cohort data might not be independent from 
each other, e.g. papers published by Lian et al., Jin et al., and Zangh, Cai et al. comprise patient data 
from the same hospital in Hangzhou (province Zhejiang, China) (23, 32, 33); this is also likely the 
case for papers published by Guan, Ni et al. and Guan, Liang et al. (13, 14). Even if the potential 
repetition of patient data is taken into account, the health status of these cohorts appear to be 
considerably better than in the underlying population, despite suffering from symptomatic 
COVID-19. The same is observed for patients from the United States, for which information on two 
comorbidities was not specific enough to be included in this evaluation. As mentioned by the 
authors, the quality of data might be compromised by the rapid evolution of the pandemic, urgency 
of medical interventions, and lack of resources, which might explain the lack of complete data on 
underlying health conditions in more than 94 % of the more than 122000 studied case reports. 
Therefore, representativeness of the data reported in the different studies for the general 
population cannot be presumed and caution has to be exercised in the interpretation of the 
outcomes of some meta-analyses due to this limitation and the mentioned potentially double 
accounting of patient data. 
The limited agreement of the reported cohort data with the general population in terms of 
prevalence of underlying health conditions other than smoking demonstrates indirectly that these 
patients most likely do not reflect the situation of the general population. In the absence of 
specifically designed studies, any hypothesis on the effect of nicotine on symptomatic COVID-19 
remains speculative. The number of potentially confounding variables would require a multivariate 
statistical approach and large cohort sizes for providing clarity on the significance of potential 
effects. However, the structure of the published aggregated data permits only univariate 
approaches. As such, the hypothesis of a potentially protective effect of nicotine on symptomatic 
COVID-19 cannot be verified. Consequently, specially designed studies are warranted for 
elucidating the effect of smoking/nicotine uptake on the development of symptomatic COVID-19. 
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Table 4: Compilation of prevalence ratios (PR) of the observed prevalence with the prevalence in 
the respective general population 
Author Country Obs. Age* PR 
  # y Smoking HT Diabetes COPD 
Zhang et al. (16) CN 133 57 0.05 1.66 1.11 0.11 
Huang et al. (18) CN 41 49 0.19 0.78 1.79 0.15 
Guan, Ni et al. (14) CN 1099 47 0.40 0.64 0.68 0.08 
Yang et al. (15) CN 52 59.7 0.11  1.59 0.50 
Guan, Liang et al (13) CN 1590 48.9 0.23 0.73 0.75 0.11 
Chen et al. (19) CN 274 62 0.08 1.83 1.57  
Liu et al. (17) CN 78 38 0.24 0.57 0.59 0.19 
Zhou et al. (20) CN 191 56 0.17 1.64 1.73 0.21 
Zhang, Cai et al. (23) CN 645 45.2 0.23 0.67 0.68 0.01 
Wang et al. (27) CN 125 38.8 0.42    
Wan et al. (22) CN 135 47 0.23 0.47 0.82 0.21 
Shi et al. (24) CN 474 46 0.28 0.87 0.55  
Feng et al. (28) CN 454 53 0.30 1.04 0.94  
Ji et al. (29) CN 208 44 0.30    
Li et al. (26) CN 544 60 0.27 1.67 1.39 0.23 
Mo et al. (21) CN 155 54 0.13 1.31 0.89 0.23 
Kim et al. (25) KR 28 42.6 0.83 0.00 0.78 0.00 
Goyal et al. (30) US 393 62.2 0.24 1.08 2.49 0.80 
CDC US 7162  0.07 0.03   
Gold et al. (36) US 305 60 0.26 1.47 4.01 0.82 
Miyara et al. (1)1 FR 341  0.24 1.29 3.64 1.05 
Miyara et al. (1)2 FR 132  0.39 0.37 0.66 0.19 
Miyara et al. (1)3 FR 473  0.28 1.04 2.78 0.80 
Han et al. (31) CN 17 40 1.00 0.33 1.08 0.49 
Jin et al. (32) CN 651 ~45 0.23 0.66 0.68 0.01 
Lian et al. (33). CN 788  0.24 0.69 0.66 0.03 
Yao et al. (34) CN 108 52 0.17 0.83 0.43 0.45** 
Zhang, Ouyang et al. 
(35) 
CN 120 45.4 0.25 0.90 0.54 0.28 
*Mean or median;    
** comprises bronchiectasis, COPD, and asthma  
1 hospitalized patients; 2 non-hospitalized patients; 3 all patients;   
PR: prevalence ratio; obs.: observed; y: years; HT: hypertension 
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